Clinical trial
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing…
NCT00089674 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00089674 |
|---|---|
| Title | AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | AMG 162, Placebo |
| Enrollment | 1,468 |
| Start date | Aug 1, 2004 |
| Primary completion | May 16, 2008 |
| Completion | May 11, 2010 |
| First posted | Aug 11, 2004 |
| Last update posted | Oct 17, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: